Biosimilars Market, By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Insulin, and Erythropoietin), By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Biosimilars Market size was valued at USD 30,409.32 Million in 2024, expanding at a CAGR of 16.29% from 2024 to 2032.
Biosimilars are biologic medical products that are highly similar to an already approved reference product, known as the originator, in terms of structure, function, and clinical efficacy. Developed after the patent expiration of the reference product, biosimilars undergo rigorous testing to demonstrate comparable quality, safety, and effectiveness. Unlike generic drugs, which are exact chemical copies of their branded counterparts, biosimilars may exhibit minor variations due to the complex nature of biologic manufacturing processes. They provide more affordable treatment options and help improve patient access to essential therapies, particularly for conditions such as cancer, rheumatoid arthritis, and diabetes.
Biosimilars Market- Market Dynamics
Economic Advantages of Biosimilars
The key driver of the biosimilars market is the growing demand for affordable biologic therapies. As the prices of originator biologics continue to rise, both healthcare systems and patients are increasingly seeking cost-effective alternatives. Biosimilars offer a more economical option without compromising safety or efficacy, helping to reduce the financial strain on healthcare providers and patients alike. This rising demand for lower-cost treatments, combined with the expiration of patents on major biologic drugs, presents substantial growth opportunities for biosimilars, particularly in markets facing significant healthcare cost pressures.
Globally, governments are actively supporting the adoption of biosimilars to control escalating healthcare costs. For example, the European Union has implemented policies encouraging biosimilar use, resulting in estimated savings of over €10 billion between 2016 and 2020. Similarly, the U.S. government, through the Biologics Price Competition and Innovation Act (BPCIA), has facilitated the approval and market entry of biosimilars, aiming to increase competition and reduce drug prices. These initiatives reflect a global commitment to improving access to affordable biologic therapies while maintaining high standards of safety and efficacy.
Biosimilars Market- Segmentation Analysis:
The global Biosimilars Market is divided into three categories: Drug Class, Indication and Region.
The biosimilars market is divided into several drug classes, each addressing specific therapeutic needs. Key categories include Monoclonal Antibodies, which are extensively used in cancer treatment, autoimmune diseases, and organ transplant therapies; Granulocyte Colony-Stimulating Factor for managing neutropenia; Insulin for diabetes control; Erythropoietin to treat anemia; Recombinant Human Growth Hormone for growth hormone deficiencies; Etanercept targeting autoimmune conditions; Follitropin for fertility treatments; Teriparatide in osteoporosis therapy; Interferons for viral infections and certain cancers; Anticoagulants to prevent blood clots; and other biologic drug classes covering diverse therapies. Among these, Monoclonal Antibodies dominate the biosimilars market due to their widespread use in oncology, rheumatoid arthritis, and inflammatory disorders. Their significant market share is also driven by the expiration of patents on several blockbuster biologics in this class, enabling biosimilar competition. According to the U.S. Food and Drug Administration (FDA), monoclonal antibody biosimilars accounted for approximately 45% of all approved biosimilars as of 2023, highlighting their pivotal role in the market.
The biosimilars market is also segmented based on therapeutic indications, catering to various medical conditions. These include Oncology, where biosimilars treat cancers such as breast, colorectal, and lung cancer; Inflammatory and Autoimmune Diseases, addressing rheumatoid arthritis, psoriasis, and similar disorders; Chronic Diseases, including diabetes and cardiovascular conditions; Blood Disorders like anemia and neutropenia; Growth Hormone Deficiency affecting both children and adults; Infectious Diseases such as Hepatitis C and HIV; and other therapeutic areas. Oncology stands out as the dominant indication for biosimilars, largely due to the high global incidence of cancer and the urgent demand for cost-effective treatment options. The loss of patent protection on multiple oncology biologics has further accelerated biosimilar adoption in this space. The National Cancer Institute (NCI) reports that cancer remains a leading cause of death worldwide, with over 1.9 million new cases estimated in the U.S. alone in 2024, underscoring the critical need for accessible biosimilar therapies in oncology.
Biosimilars Market- Geographical Insights
The global biosimilars market is distributed across North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa, with each region contributing based on their healthcare infrastructure, regulatory environment, and market demand.
North America holds a dominant share of the biosimilars market, primarily driven by the United States. The U.S. represents one of the largest markets for biosimilars, fueled by strong demand for affordable biologic therapies, a well-established healthcare system, and robust regulatory support from the Food and Drug Administration (FDA). The expiration of patents for several blockbuster biologics, especially in oncology and autoimmune diseases, has accelerated biosimilar adoption. Additional factors such as increasing healthcare costs, a growing aging population, and a rising number of biosimilar approvals contribute to market growth. Furthermore, government policies aimed at reducing drug spending, coupled with incentives from private insurers to promote biosimilar use, have reinforced market expansion in this region.
Europe is another key player in the biosimilars market, led by countries including Germany, the United Kingdom, and France. The European Medicines Agency (EMA) has played a crucial role in facilitating the development and approval of biosimilars, creating a supportive regulatory framework. European countries have widely embraced biosimilars as a strategy to lower healthcare costs, particularly for chronic conditions such as cancer and rheumatoid arthritis. The proven cost-effectiveness and clinical efficacy of biosimilars have driven high adoption rates across the continent. Strong governmental backing and favorable pricing policies have enabled biosimilars to achieve significant market penetration, solidifying Europe’s position as a leading region in the global biosimilars market.
Biosimilars Market- Competitive Landscape:
The biosimilars market is led by major pharmaceutical companies such as Novartis AG, Pfizer Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd., all of which possess extensive biosimilar portfolios and strong research and development capabilities. These industry leaders focus on expanding their offerings, particularly in high-demand therapeutic areas like oncology, autoimmune diseases, and chronic conditions, to capture a larger share of the rapidly growing market. Alongside these established players, companies such as Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, and Celltrion Healthcare are making significant advances with innovative biosimilars, securing regulatory approvals in key markets including the U.S. and Europe. Additionally, emerging entrants like Biocon and Kashiv Biosciences are leveraging cost-effective production strategies and deep regional market knowledge to compete with established firms. This competitive landscape fosters continuous innovation and price competition, ultimately improving patient access to biologic treatments.
Recent Developments:
- In June 2024, the U.S. Food and Drug Administration (FDA) issued new draft guidance allowing biosimilar manufacturers to demonstrate interchangeability using existing datasets. This change is expected to reduce the need for additional switching studies, streamline the approval process, and boost market competition.
- In May 2024, Biocon Biologics’ aflibercept biosimilar, branded as YESAFILI, received FDA approval, marking Biocon’s entry into the U.S. ophthalmology market and providing a more affordable treatment option for retinal disorders.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOSIMILARS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly And Company
- Teva Pharmaceutical Industries
- Fresenius Kabi AG
- Stada Arzneimittel AG
- Boehringer Ingelheim International Gmbh
- F. Hoffmann-La Roche Ltd
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics
- Coherus Biosciences
- Biocon
- Amega Biotech
- Apotex Inc.
- Biocad
- Mabxience
- Probiomed
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Reliance Life Sciences
- Kashiv Biosciences, LLC
- Usv Private Limited
- Amneal Pharmaceuticals, Inc.
- Others
GLOBAL BIOSIMILARS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Monoclonal Antibodies
- Infliximab
- Rituximab
- Trastuzumab
- Adalimumab
- Other Monoclonal Antibodies
- Granulocyte Colony-Stimulating Factor
- Insulin
- Erythropoietin
- Recombinant Human Growth Hormone
- Etanercept
- Follitropin
- Teriparatide
- Interferons
- Anticoagulants
- Other Drug Classes
GLOBAL BIOSIMILARS MARKET, BY INDICATION - MARKET ANALYSIS, 2019 - 2032
- Oncology
- Inflammatory & Autoimmune Diseases
- Chronic Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Infectious Diseases
- Other Indications
GLOBAL BIOSIMILARS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Biosimilars Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Biosimilars Market Snippet by Drug Class
2.1.2. Biosimilars Market Snippet by Indication
2.1.3. Biosimilars Market Snippet by Country
2.1.4. Biosimilars Market Snippet by Region
2.2. Competitive Insights
3. Biosimilars Key Market Trends
3.1. Biosimilars Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Biosimilars Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Biosimilars Market Opportunities
3.4. Biosimilars Market Future Trends
4. Biosimilars Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Biosimilars Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Biosimilars Market Landscape
6.1. Biosimilars Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Biosimilars Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
7.1.2. Monoclonal Antibodies
7.1.2.1. Infliximab
7.1.2.2. Rituximab
7.1.2.3. Trastuzumab
7.1.2.4. Adalimumab
7.1.2.5. Other Monoclonal Antibodies
7.1.3. Granulocyte Colony-Stimulating Factor
7.1.4. Insulin
7.1.5. Erythropoietin
7.1.6. Recombinant Human Growth Hormone
7.1.7. Etanercept
7.1.8. Follitropin
7.1.9. Teriparatide
7.1.10. Interferons
7.1.11. Anticoagulants
7.1.12. Other Drug Classes
8. Biosimilars Market – By Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
8.1.2. Oncology
8.1.3. Inflammatory & Autoimmune Diseases
8.1.4. Chronic Diseases
8.1.5. Blood Disorders
8.1.6. Growth Hormone Deficiency
8.1.7. Infectious Diseases
8.1.8. Other Indications
9. Biosimilars Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2. North America
9.2.1. Overview
9.2.2. Biosimilars Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Biosimilars Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.7. France
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.7.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.7.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.8. Italy
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.9. Spain
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.10. United Kingdom
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.11. Russia
9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.12. Netherlands
9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.13. Sweden
9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.14. Poland
9.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3.15. Rest of Europe
9.3.15.1. Overview
9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Biosimilars Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.6. India
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.6.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.8. South Korea
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.8.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.8.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.9. Japan
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.11. Thailand
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.11.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.12. Indonesia
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5. Latin America
9.5.1. Overview
9.5.2. Biosimilars Key Manufacturers in Latin America
9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa
9.6.1. Overview
9.6.2. Biosimilars Key Manufacturers in Middle East and Africa
9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.7. United Arab Emirates
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.7.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Biosimilars Industry
10.1. Competitive Dashboard
10.2. Company Profiles
10.2.1. Novartis Ag
10.2.2. Pfizer Inc.
10.2.3. Amgen Inc.
10.2.4. Dr. Reddy’s Laboratories Ltd.
10.2.5. Eli Lilly And Company
10.2.6. Teva Pharmaceutical Industries
10.2.7. Fresenius Kabi Ag
10.2.8. Stada Arzneimittel Ag
10.2.9. Boehringer Ingelheim International Gmbh
10.2.10. F. Hoffmann-La Roche Ltd
10.2.11. Celltrion Healthcare Co., Ltd.
10.2.12. Samsung Biologics
10.2.13. Coherus Biosciences
10.2.14. Biocon
10.2.15. Amega Biotech
10.2.16. Apotex Inc.
10.2.17. Biocad
10.2.18. Mabxience
10.2.19. Probiomed
10.2.20. Fujifilm Kyowa Kirin Biologics Co., Ltd.
10.2.21. Intas Pharmaceuticals Ltd.
10.2.22. Reliance Life Sciences
10.2.23. Kashiv Biosciences, Llc
10.2.24. Usv Private Limited
10.2.25. Amneal Pharmaceuticals, Inc.
10.2.26. Others
11. 360 Degree Analyst View
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
